title: Rapid regression of retinal hemorrhage and neovascularization in a case of familial exudative vitreoretinopathy treated with intravitreal bevacizumab.
abstract: OBJECTIVE
  To report a case of familial exudative vitreoretinopathy (FEVR) rapidly resolved by intravitreal injection of bevacizumab.
  
  
  METHODS
  A 36-year-old woman complained about floaters and visual field defect. Funduscopic examinations revealed retinal vessel anastomosis located between the equator and ora serrata in both eyes. The right eye was accompanied with slight vitreous hemorrhage. Since the patient declined retinal cryopexy for cosmetic reasons, intravitreal bevacizumab injections (1.25 mg/0.05 ml) were performed in both eyes.
  
  
  RESULTS
  Treatment resulted in the rapid regression and the accelerated fibrosis of neovascular tissues. At 4-month follow-up in the right eye and 1-month follow-up in the left, no signs of systemic or ocular complications were detected.
  
  
  CONCLUSIONS
  Intravitreal injection of bevacizumab may be considered as an alternative method in treating FEVR.
authors.affiliation: Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
authors.forename: Mizuki
authors.initials: M
authors.lastname: Tagami
authors.forename: Sentaro
authors.initials: S
authors.lastname: Kusuhara
authors.forename: Shigeru
authors.initials: S
authors.lastname: Honda
authors.forename: Yasutomo
authors.initials: Y
authors.lastname: Tsukahara
authors.forename: Akira
authors.initials: A
authors.lastname: Negi
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005122:Exudates and Transudates / Q000378:metabolism; D005128:Eye Diseases / Q000150:complications / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D005260:Female; D005654:Fundus Oculi; D006801:Humans; D007267:Injections; D009389:Neovascularization, Pathologic / Q000209:etiology* / Q000473:pathology; D012074:Remission Induction; D012164:Retinal Diseases / Q000150:complications / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D012166:Retinal Hemorrhage / Q000209:etiology* / Q000473:pathology; D012171:Retinal Vessels; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab
references.citation: Fortschr Ophthalmol. 1989;86(3):221-3
references.pmid: 2759534
references.citation: Am J Ophthalmol. 2006 Jul;142(1):1-9
references.pmid: 16815245
references.citation: Retina. 2006 Mar;26(3):275-8
references.pmid: 16508426
references.citation: Am J Ophthalmol. 1969 Oct;68(4):578-94
references.pmid: 5394449
references.citation: Retina. 2008 Jun;28(6):831-8
references.pmid: 18536599
references.citation: Retina. 2006 Mar;26(3):279-84
references.pmid: 16508427
references.citation: Graefes Arch Clin Exp Ophthalmol. 2008 Jul;246(7):1061-3
references.pmid: 18320201